Entering text into the input field will update the search result below

Galapagos and MorphoSys launch early-stage study of subcutaneous MOR106 in dermatitis

Sep. 13, 2018 4:10 PM ETGalapagos NV (GLPG) StockBy: Douglas W. House, SA News Editor
  • Galapagos NV (NASDAQ:GLPG) and collaboration partner MorphoSys AG (MOR) announce the initiation of a Phase 1 bridging study evaluating a subcutaneous formulation of anti-IL117C antibody MOR106 in patients with moderate-to-severe atopic dermatitis.
  • Part 1 of the study will be an open-label dose-ranging trial in healthy volunteers. Part 2 will assess the efficacy of multiple doses against placebo.
  • Novartis Pharma AG owns global development and commercialization rights.
  • Previously: Galapagos and MorphoSys out-license MOR106 to Novartis for up to $1.1B (July 19)

Recommended For You

More Trending News

About GLPG Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GLPG--
Galapagos NV